OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press40510.17650/1818-8346-2020-15-1-51-58DIAGNOSIS AND TREATMENT OF HEMOBLASTOSESДИАГНОСТИКА И ЛЕЧЕНИЕ ГЕМОБЛАСТОЗОВImmune thrombocytopenia at the patient with a cystadenoma of the ovaries (а clinical case)Особенности течения иммунной тромбоцитопении у пациентки с цистоаденомой яичников (клинический случай)PluzhnikovaN. A.ПлужниковаН. А.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 23

https://orcid.org/0000-0002-9454-0002GruzdevV. E.ГруздевВ. Е.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 23

https://orcid.org/0000-0002-5889-0689ByalikT. E.БяликТ. Е.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478; Build. 2, 8 Trubetskaya St., Moscow 119991

115478 Москва, Каширское шоссе, 23; 119991 Москва, ул. Трубецкая, 8, стр. 2

MustafinaE. A.МустафинаЕ. А.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 23

https://orcid.org/0000-0002-5769-3114DavydovaT. V.ДавыдоваТ. В.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 23

https://orcid.org/0000-0003-1564-424XZeinalovaP. A.ЗейналоваП. А.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478; Build. 2, 8 Trubetskaya St., Moscow 119991

115478 Москва, Каширское шоссе, 23; 119991 Москва, ул. Трубецкая, 8, стр. 2

ShikhabovaZ. S.ШихабоваЗ. С.
Russian Federation

Build. 2, 8 Trubetskaya St., Moscow 119991

119991 Москва, ул. Трубецкая, 8, стр. 2

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский университет)1904202015151581804202018042020https://oncohematology.abvpress.ru/ongm/article/view/405

Immune thrombocytopenia is an immunosuppressed acquired disease characterized by low platelet levels in peripheral blood and an increased risk of bleeding. This pathology deserves special attention in cases of patients who are scheduled for surgery, which undoubtedly requires careful preparation of the patient for surgery and a complete laboratory analysis, including a thromboelastogram.

This article describes the clinical case of successful surgical treatment of a patient with immune thrombocytopenia. 

Иммунная тромбоцитопения – иммунообусловленное приобретенное заболевание, характеризующееся низким уровнем тромбоцитов в периферической крови и повышенным риском кровотечения. Данная патология заслуживает особого внимания при необходимости выполнения оперативного вмешательства, что, несомненно, требует тщательной подготовки пациента и проведения комплексного лабораторного обследования, включая тромбоэластограмму.

В данной статье приводится описание клинического случая успешного хирургического лечения пациентки с иммунной тромбоцитопенией. 

immune thrombocytopeniathromboelastometrysurgeryиммунная тромбоцитопениятромбоэластометрияоперативное вмешательствоNeylon A.J., Saunders P.W., Howard M.R. et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population­based cohort of 245 patients. Br J Haematol 2003;122(6):966–74. DOI: 10.1046/j.1365­2141.2003.04547.x.Terrell D.R., Beebe L.A., Vesely S.K. et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 2010;85(3):174–80. DOI: 10.1002/ajh.21616.Terrell D.R., Beebe L.A., Vesely S.K. et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 2010;85(3):174–80. DOI: 10.1002/ajh.21616.Lambert M.P., Gernsheimer T.B. Clinical updates in adult immune thrombocytopenia. Blood 2017;129(21):2829–35. DOI: 10.1182/blood­2017­03­754119.McMillan R., Wang L., Tomer. A. et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103(4):1364–9. DOI: 10.1182/blood­2003­08­2672.Zhao C., Li X., Zhang F. et al. Increased cytotoxic T­lymphocyte­mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008;93(9):1428–30. DOI: 10.3324/haematol.12889.Kuwana M., Kaburaki J., Ikeda Y. Autoreactive T cells to platelet GPIIb–IIIa in immune thrombocytopenic purpura. Role inproduction of anti­platelet autoantibody. J Clin Invest 1998;102(7):1393–402. DOI: 10.1172/JCI4238.Nugent D., McMillan R., Nichol J.L., Slichter S.J. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009;146(6):585–96. DOI: 10.1111/j.1365­2141.2009.07717.x.Nugent D., McMillan R., Nichol J.L., Slichter S.J. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009;146(6):585–96. DOI: 10.1111/j.1365­2141.2009.07717.x.Rodeghiero F., Stasi R., Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113(11):2386–93. DOI: 10.1182/blood­2008­07­162503.Neunert C., Lim W., Crowther M. et al. The American Society of Hematology 2011 evidence­based practice guideline for immune thrombocytopenia. Вlood 2011;117(16):4198–204. DOI: 10.1182/blood­2010­08­302984.Provan D., Stasi R., Newland A.C. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168–86. DOI: 10.1182/blood­2009­06­225565.Cohen Y.C., Djuibegovic B., ShamaiLubovitz O., Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Int Med 2000;160(11):1630–8. DOI: 10.1001/archinte.160.11.1630.Arnold D.M., Nazy I., Clare R. et al. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood Adv 2017;1(25):2414–20. DOI: 10.1182/bloodadvances.2017010942.Altintas A., Ozel A., Okur N. et al. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura. J Thromb Thrombolysis,2007;24(2):163–8. DOI: 10.1007/s11239­007­0031­y.Altintas A., Ozel A., Okur N. et al. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura. J Thromb Thrombolysis,2007;24(2):163–8. DOI: 10.1007/s11239­007­0031­y.Melboucy­Belkhir S., Khellaf M., Augier A. et al. Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. Am J Hematol 2016;91(12):E499–501. DOI: 10.1002/ajh.24529.Grimaldi­Bensouda L., Nordon C., Michel M. et al. Group for the PGRx­ITP Study. Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome. Haematologica 2016;101(9):1039–45. DOI: 10.3324/haematol.2016.146373.Grimaldi­Bensouda L., Nordon C., Michel M. et al. Group for the PGRx­ITP Study. Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome. Haematologica 2016;101(9):1039–45. DOI: 10.3324/haematol.2016.146373.Segal J.B., Powe N.R. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006;4(11):2377–83. DOI: 10.1111/j.1538­7836.2006.02147.x.Segal J.B., Powe N.R. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006;4(11):2377–83. DOI: 10.1111/j.1538­7836.2006.02147.x.Gulidova O.V. If surgery is planned. Available at: http:/www.unimedao.ru/articles/6826/9673/item/34. (In Russ.).Гулидова О.В. Если предстоит операция. Доступно по: http://www. unimedao.ru/articles/6826/9673/item/34.Yarets Yu.I. Thromboelastography: basic parameters, the interpretation of results. Gomel: RSC RMHE, 2018. 26 p. (In Russ.).Ярец Ю.И. Тромбоэластография: основные показатели, интерпретация результатов. Гомель: ГУ «РНПЦ РМиЭЧ», 2018. 26 с.Cuker A., Cines D.B., Neunert C.E. Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol 2016;23(5):479–85. DOI: 10.1097/MOH.0000000000000270.Cuker A., Cines D.B., Neunert C.E. Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol 2016;23(5):479–85. DOI: 10.1097/MOH.0000000000000270.Din B., Wang X., Shi Y., Li Y. Long­term effect of high­dose dexamethasone with or without low­dose dexamethasone maintenance in untreated immune thrombocytopenia. Acta Haematol 2015;133(1):2124–8. DOI: 10.1159/000362529.Matschke J., Müller­Beissenhirtz H., Novotny J. et al. A randomized trial of daily prednisone versus pulsed dexamethasone in treatment­naive adult patients with immune thrombocytopenia: EIS 2002 Study. Acta Haematol 2016;136(2):101–7. DOI: 10.1159/000445420.Kojouri K., Vesely S.K., Terrell D.R. et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long­term platelet count responses, prediction of response, and surgical complications. Blood 2004;104(9):2623–34. DOI: 10.1182/blood­2004­03­1168.Thai L.H., Mahevas M., Roudot­Thoraval F. et al. Long­term complications after splenectomy in adult chronic immune thrombocytopenia with a minimum follow up of 10 years. First results from a singlecenter case­control study in 140 patients with primary ITP. Program and abstracts of the 56th Annual Meeting of the American Society of Hematology. December 6–9, 2014. San Francisco, California. Abstract 232.GuanY., Wang S., Xue F. et al. Long­term results of splenectomy in adult chronic immune thrombocytopenia. Eur J Haematol 2017;98(3):235–41. DOI: 10.1111/ejh.12821.GuanY., Wang S., Xue F. et al. Long­term results of splenectomy in adult chronic immune thrombocytopenia. Eur J Haematol 2017;98(3):235–41. DOI: 10.1111/ejh.12821.Cooper N., Stasi R., Cunningham­Rundles S. et al. The efficacy and safety of B­cell depletion with anti­CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125(2):232–9. DOI: 10.1111/j.1365­2141.2004.04889.x.Cooper N., Stasi R., Cunningham­Rundles S. et al. The efficacy and safety of B­cell depletion with anti­CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125(2):232–9. DOI: 10.1111/j.1365­2141.2004.04889.x.Zaja F., Baccarani M., Mazza P. et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010;155(14):2755–62. DOI: 10.1182/blood­2009­07­229815.Patel V.L., Mahevas M., Lee S.Y. et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012;119(25):5989–95. DOI: 10.1182/blood­2011­11­393975.Marangon M., Vianelli N., Palandri F. et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long­term response. Eur J Haematol 2017;98(4):371–7. DOI: 10.1111/ejh.12839.Mazza P., Minoia C., Melpignano A. et al. The use of thrombopoietin­receptor agonists (TPO­RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol 2016;95(2):239–44. DOI: 10.1007/s00277­015­2556­z.Mazza P., Minoia C., Melpignano A. et al. The use of thrombopoietin­receptor agonists (TPO­RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol 2016;95(2):239–44. DOI: 10.1007/s00277­015­2556­z.González­López T.J., Alvarez­Román M.T., Pascual C. et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol 2016;97(3):297–302. DOI: 10.1111/ejh.12725.Saleh M.N., Bussel J.B., Cheng G. et al. EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long­term, open­label EXTEND study. Blood 2013;121(3):537–45. DOI: 10.1182/blood­2012­04­425512.Saleh M.N., Bussel J.B., Cheng G. et al. EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long­term, open­label EXTEND study. Blood 2013;121(3):537–45. DOI: 10.1182/blood­2012­04­425512.Nagalla S. Platelet response to avatrombopag in patients with chronic immue thrombocytopenia. ASH 2019. Abstract 1071.Panzer S., Rieger M., Vormittag R., Eichelberger B. et al. Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia. Eur J Clin Invest 2007;37(10):814–9. DOI: 10.1111/j.1365­2362.2007. 01855.x.Panzer S., Rieger M., Vormittag R., Eichelberger B. et al. Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia. Eur J Clin Invest 2007;37(10):814–9. DOI: 10.1111/j.1365­2362.2007. 01855.x.